NIH and partners to launch HIV vaccine efficacy trial in the Americas and Europe

(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news